Publisert 19.06.2017

Regenics joins consortium for biological drug development receiving 16 mill SEK from Vinnova

Regenics Norway joins international consortium funded by 16 mill SEK from Vinnova, Sweden

Vinnova announced today an alloocation of 16 mill SEK to the BioNext consortium consisting of companies seeking to innovate in biological drug development. Regenics As, Oslo Norway is one of the contributors and beneficiaries of the grant from Vinnova.


Regenics AS has developed a number of assays and techniques to study effects of various substances on skin cells both in vitroin vivo and in the clinic. Our focus is to develop products and techniques for therapeutic skin applications and to improve skin appearance.